Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jan;114(2):558–562. doi: 10.1111/j.1476-5381.1995.tb13263.x

Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity.

S E Banner 1, G J Sanger 1
PMCID: PMC1510257  PMID: 7881756

Abstract

1. Noxious colo-rectal distension was applied in conscious rats by acute balloon inflation and the effects observed as abdominal muscle contraction with the threshold typically between 10-40 mmHg. The effects of 5-HT3 receptor antagonists on responses to noxious colo-rectal distension were then studied in both normal rats and those pretreated with 5-hydroxytryptophan (5-HTP). 2. Granisetron and ondansetron (10 micrograms kg-1 and 1 mg kg-1, s.c.) had no effect on visceromotor thresholds to colo-rectal distension in normal rats. 3. Hypersensitivity of the colo-rectum was achieved by systemic administration of a low dose of 5-HTP (10 mg kg-1, s.c.) which lowered the distension pressure required to induce the visceromotor reflex; analysis of variance showed a highly significant treatment effect (F1,11 = 84.26, P < 0.001). 4. Granisetron, zatosetron, bemesetron and renzapride equi-potently increased the threshold values at which distension evoked a visceromotor reflex after dosing with 5-HTP, with a maximal response 3.6 to 4.2 fold above saline controls, at 10 micrograms kg-1, s.c. Metoclopramide (10 micrograms kg-1) also raised the level of distension required to elicit a response. By comparison, tropisetron caused a small, non-significant increase in visceromotor threshold values and only at high doses (1 mg kg-1), whilst ondansetron and BRL 46470 had no significant effects at doses up to 10 mg kg-1. 5. The response to granisetron (10 micrograms kg-1, s.c.) in 5-HTP-treated rats was unaltered by pre-administration of naloxone (5 mg kg-1, s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
559

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Couturier E. G., Hering R., Foster C. A., Steiner T. J., Clifford Rose F. First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache. 1991 May;31(5):296–297. doi: 10.1111/j.1526-4610.1991.hed3105296.x. [DOI] [PubMed] [Google Scholar]
  2. Danzebrink R. M., Gebhart G. F. Evidence that spinal 5-HT1, 5-HT2 and 5-HT3 receptor subtypes modulate responses to noxious colorectal distension in the rat. Brain Res. 1991 Jan 4;538(1):64–75. doi: 10.1016/0006-8993(91)90377-8. [DOI] [PubMed] [Google Scholar]
  3. Ferrari M. D., Wilkinson M., Hirt D., Lataste X., Notter M. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group. Pain. 1991 Jun;45(3):283–291. doi: 10.1016/0304-3959(91)90052-Y. [DOI] [PubMed] [Google Scholar]
  4. Fozard J. R. MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1984 May;326(1):36–44. doi: 10.1007/BF00518776. [DOI] [PubMed] [Google Scholar]
  5. Gebauer A., Merger M., Kilbinger H. Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):137–140. doi: 10.1007/BF00169258. [DOI] [PubMed] [Google Scholar]
  6. Glaum S. R., Proudfit H. K., Anderson E. G. 5-HT3 receptors modulate spinal nociceptive reflexes. Brain Res. 1990 Feb 26;510(1):12–16. doi: 10.1016/0006-8993(90)90721-m. [DOI] [PubMed] [Google Scholar]
  7. Hammer J., Phillips S. F., Talley N. J., Camilleri M. Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther. 1993 Oct;7(5):543–551. doi: 10.1111/j.1365-2036.1993.tb00131.x. [DOI] [PubMed] [Google Scholar]
  8. Hughes J. B. Metoclopramide in migrane treatment. Med J Aust. 1977 Oct 22;2(17):580–580. [PubMed] [Google Scholar]
  9. Kandler D., Lisander B. Analgesic action of metoclopramide in prosthetic hip surgery. Acta Anaesthesiol Scand. 1993 Jan;37(1):49–53. doi: 10.1111/j.1399-6576.1993.tb03597.x. [DOI] [PubMed] [Google Scholar]
  10. Loisy C., Beorchia S., Centonze V., Fozard J. R., Schechter P. J., Tell G. P. Effects on migraine headache of MDL 72,222, an antagonist at neuronal 5-HT receptors. Double-blind, placebo-controlled study. Cephalalgia. 1985 Jun;5(2):79–82. doi: 10.1046/j.1468-2982.1985.0502079.x. [DOI] [PubMed] [Google Scholar]
  11. Mayer E. A., Raybould H. E. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology. 1990 Dec;99(6):1688–1704. doi: 10.1016/0016-5085(90)90475-g. [DOI] [PubMed] [Google Scholar]
  12. Moss H. E., Sanger G. J. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol. 1990 Jul;100(3):497–501. doi: 10.1111/j.1476-5381.1990.tb15836.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ness T. J., Gebhart G. F. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat. Brain Res. 1988 May 31;450(1-2):153–169. doi: 10.1016/0006-8993(88)91555-7. [DOI] [PubMed] [Google Scholar]
  14. Ness T. J., Gebhart G. F. Visceral pain: a review of experimental studies. Pain. 1990 May;41(2):167–234. doi: 10.1016/0304-3959(90)90021-5. [DOI] [PubMed] [Google Scholar]
  15. Prior A., Read N. W. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1993 Apr;7(2):175–180. doi: 10.1111/j.1365-2036.1993.tb00087.x. [DOI] [PubMed] [Google Scholar]
  16. Rosenblatt W. H., Cioffi A. M., Sinatra R., Saberski L. R., Silverman D. G. Metoclopramide: an analgesic adjunct to patient-controlled analgesia. Anesth Analg. 1991 Nov;73(5):553–555. doi: 10.1213/00000539-199111000-00007. [DOI] [PubMed] [Google Scholar]
  17. Rowat B. M., Merrill C. F., Davis A., South V. A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department. Cephalalgia. 1991 Nov;11(5):207–213. doi: 10.1046/j.1468-2982.1991.1105207.x. [DOI] [PubMed] [Google Scholar]
  18. Sanger G. J. New antiemetic drugs. Can J Physiol Pharmacol. 1990 Feb;68(2):314–324. doi: 10.1139/y90-046. [DOI] [PubMed] [Google Scholar]
  19. Steadman C. J., Talley N. J., Phillips S. F., Zinsmeister A. R. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc. 1992 Aug;67(8):732–738. doi: 10.1016/s0025-6196(12)60797-6. [DOI] [PubMed] [Google Scholar]
  20. Zifa E., Fillion G. 5-Hydroxytryptamine receptors. Pharmacol Rev. 1992 Sep;44(3):401–458. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES